Abiomed Passes Midway Point Of AbioCor Trial With Eighth Implant
This article was originally published in The Gray Sheet
Executive Summary
Eight Abiomed AbioCor total artificial hearts have been implanted as of Jan. 7, marking the halfway-point of the company's clinical trial to support a PMA application in 2004
You may also be interested in...
Abiomed AbioCor Proxy Consent Policy Will Hasten Pace Of Trial Enrollment
Abiomed's decision to allow relatives to provide informed consent for patient participation in the AbioCor artificial heart trial should ensure a greater number of patients will be eligible for implantation
Abiomed AbioCor Proxy Consent Policy Will Hasten Pace Of Trial Enrollment
Abiomed's decision to allow relatives to provide informed consent for patient participation in the AbioCor artificial heart trial should ensure a greater number of patients will be eligible for implantation
AbioMed AbioCor Artificial Heart Cost Effectiveness Hinges On Longevity
AbioMed eventually must show that the AbioCor implantable artificial heart can extend a patient's life at least three years to justify the nearly $300,000 average cost of each implant, according to company consultant Mehmet Oz, MD.